Skip to main content

Table 2 Clinical characteristics of participants genotyped using Axiom and MEGA arrays (stage 1b and 1c)

From: Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans

  WFSM-Axiom WFSM-MEGA
T2D-ESKD Non-diabetic non-nephropathy T2D-lacking nephropathy T2D-ESKD Non-diabetic non-nephropathy T2D-lacking nephropathy Non-diabetic ESKD
N 1700 770 663 219 908 201 1910
Females (%) 56 49 64 49 59 62 41
Age (years) 62.0 ± 10.8 47.9 ± 12.0 55.7 ± 11.6 62.0 ± 11.0 44.8 ± 13.9 55.8 ± 9.5 55.4 ± 14.4
Age of onset of diabetes (years) 39.7 ± 12.8 46.2 ± 12.3 37.8 ± 9.6 43.7 ± 10.3
Duration of diabetes prior to ESKD (years) 19.1 ± 10.0 20.4 ± 9.5
Duration of ESKD (years) 3.6 ± 3.6 4.1 ± 3.1 6.2 ± 5.8
Fasting serum glucose (mg/dl) 184 ± 89 96 ± 22 163 ± 92 127 ± 33 96 ± 11 174 ± 62 90 ± 3
eGFR (ml/min/1.73m2) 96.0 ± 20.8 91.3 ± 19.7 85.9 ± 17.3 95.2 ± 17.3
Body mass index (kg/m2) 30.7 ± 7.1 29.6 ± 7.4 33.1 ± 7.8 30.8 ± 7.0 29.7 ± 6.6 33.0 ± 6.5 27.8 ± 7.2
  1. Categorical data expressed as percentage; continuous data as mean ± SD
  2. Abbreviations: T2D type 2 diabetes, ESKD end-stage kidney disease, N number, eGFR estimated glomerular filtration rate